PRIME-HCC Trial
Cross-source consensus on PRIME-HCC Trial from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Other
Other
Other
Other
Highlighted claims
- PRIME-HCC is a pragmatic two-arm parallel randomised controlled trial evaluating ePRO-based symptom monitoring for HCC patients receiving immunotherapy in China. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
- The trial plans to recruit about 238 HCC patients receiving immunotherapy and allocate them 1:1 to intervention or control. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
- The trial evaluates both clinical effectiveness and implementation outcomes. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
- PRIME-HCC is registered as NCT06938945 and follows SPIRIT 2013 protocol guidance. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
- Recruitment and data collection began in May 2025 and are scheduled to end in August 2026. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
- Eligible participants must be adults aged 18 to 75 with HCC, immunotherapy treatment, protocol participation capacity, and Mandarin Chinese comprehension. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial